drugset / Trial / NCT03961308

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961308

Phase 1 Completed 204 enrolled Takeda
RandomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to compare the PK of single dose of Vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.

Timeline

Start
2018-03-12
Primary completion
2018-10-20
Completion
2018-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Vedolizumab Monoclonal antibody 108 mg Subcutaneous

Indications

No indication recorded.